The Association of Antidepressant Medication and Body Weight Gain

Ranjbar, Sara and Pai, Nagesh Brahmavar and Deng, Chao (2013) The Association of Antidepressant Medication and Body Weight Gain. [Journal (On-line/Unpaginated)]

Full text available as:

PDF - Published Version
Available under License Creative Commons Attribution No Derivatives.



Objective: To review the literature and discover which antidepressants are responsible for weight gain and then to discuss the areas with lack of adequate knowledge. Method: An electronic search was conducted through Medline, Pubmed, Cochrane library, and ScienceDirect. Forty nine empirical researches were identified and reviewed. Results: Amitriptyline, clomipramine, and mirtazapine have been associated with more weight gain induction in clinical studies, but not in animal-based studies. All TCAs have been reported to cause weight gain except protriptyline. MAOIs have been associated with weight gain. In SSRI group, citalopram and ecitalopram induce weight, yet mixed results exist for paroxetine and fluoxetine. Researches unanimously reported weight loss effect for bupropion. Some studies suggest contributing factors in the relationship of antidepressants with body weight changes including age, gender, base-line weights and treatment duration. Various results of different treatment durations have been reported in some cases but there are not continuous time-dependent studies for the influences of antidepressants on body weight changes. Conclusion: More studies are required to discover underlying mechanisms and the time-dependent effects of antidepressants on body weight changes.

Item Type:Journal (On-line/Unpaginated)
Keywords:Antidepressants; Body weight; Obesity
Subjects:JOURNALS > Online Journal of Health and Allied Sciences
Neuroscience > Neuropharmacology
ID Code:9135
Deposited By: Kakkilaya Bevinje, Dr. Srinivas
Deposited On:25 Feb 2014 12:40
Last Modified:25 Feb 2014 12:40

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. Nihalani N, Schwartz TL, Siddiqui UA, Megna, JL. Obesity and psychotropics, CNS neuroscience & therapeutics. 2012;18;57–63.

2. World Health Organization. Obesity and overweight; Fact sheet N°311. Available at: Accessed May 4th, 2012.

3. World Health Organization. Mental health; Depression. Available at: Accessed May 4th, 2012.

4. Wild B, Herzog W, Lechner S, Niehoff D, Brenner H, Müller H, Rothenbacher D, Stegmaier C, Raum E. Gender specific temporal and cross-sectional associations between BMI-class and symptoms of depression in the elderly. Journal of Psychosomatic Research. 2012;72:376-382.

5. Kivimäki M, Batty D, Singh-Manoux A, Nabi H, Sabia S, Tabak A, Tasnime N, Akbaraly T, Vahtera J, Marmot M, Jokela M. Association between common mental disorder and obesity over the adult life course. The British journal of psychiatry: the Journal of mental science. 2009;195:149–155.

6. Simon G, Von Korff M, Saunders K, Miglioretti D, Crane P, Belle G, Kessler R. Association Between Obesity and Psychiatric Disorders in the US Adult Population. Archives of General Psychiatry. 2006;63:824–830.

7. Roberts RE et al. Prospective association between obesity and depression: evidence from the Alameda County Study. International journal of obesity and related metabolic disorders. Journal of the International Association for the Study of Obesity. 2003;27(4):514.

8. McCarty CA, Kosterman R, Mason W, McCauley E, Hawkins D, Herrenkohl T, Lengua L. Longitudinal associations among depression, obesity and alcohol use disorders in young adulthood, General Hospital Psychiatry. 2009;31:442–450.

9. Ball K, Burton N, Brown W. A Prospective Study of Overweight, Physical Activity, and Depressive Symptoms in Young Women. Obesity. 2008;17:66-71.

10. Heo M, Pietrobelli A, Fontaine KR, Sirey JA, Faith MS. Depressive mood and obesity in US adults: comparison and moderation by sex, age, and race. International Journal of Obesity. 2006;30:513–519.

11. Afari N, Noonan C, Goldberg J, Roy-Byrne P, Schur E, Golnari G, Buchwald D. Depression and Obesity: Do Shared Genes Explain the Relationship? Depression And Anxiety. 2010;27:799-806.

12. Kazes M, Danion JM, Grange D, et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect disord. 1994;30:193-207.

13. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res. 1998;26:265–271.

14. Schatzberg A, Cole J, DeBattista C. Manual of Clinical Psychopharmacology [Internet]. 7th Edition, American Psychiatric Publishing, Inc. 1000 Wilson Boulevard, 2012 [cited 2012 Sep 12]. Available from:

15. Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology, McGraw Hill Companies, 12th ed, 2012.

16. Paykel ES, Mueller PS, De La Vergne PM. Amitriptyline, weight gain and carbohydrate craving: A side effect. Br J Psychiatry. 1973;123:501-507.

17. Hecht-Orzack M, Cole JO, Friedman L, Bird M, McEachern J. Weight changes in antidepressants: a comparison of amitriptyline and trazodone. Neuropsychobiology. 1986;15:28-30.

18. Pande AC, Grunhaus LJ, Haskett RF, Greden JF. Weight change with antidepressant treatment. Biological Psychiatry. 1989;25:A55.

19. Joubert AT, Gagiano CA, Joubert G. Antidepressants and weight. Behavioural Pharmacology. 1995;6:30.

20. Montgomery SA, Reimitz PE, Zivkoz M. Mirtazapine versus amitriptyline in long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 1998;13:63-73.

21. Hinze-Selch D, Schuld A, Kraus T, Kuhn M, Uhr M, Haack M, Pollmacher T. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology. 2000;23:13–19.

22. Berilgen MS, Bulut S, Gonen M, Tekatas A, Dag E, Mungen, B. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia. 2005:25:1048.

23. Nobrega J, Coscinaa D. Effects of chronic amitriptyline and desipramine on food intake and body weight in rats. Pharmacology Biochemistry and Behavior. 1987;27:105–112.

24. Jeon HT, Joe GH, Kee BS. The effects of antidepressants on the weight, blood glucose, leptin, and adiponectin in diabetic (OLETF) and non diabetic (LETO) rats, European Neuropsychopharmacology. 2008;18:S349-S349.

25. Wade A, Overo KF, Lemming O, et al. Weight monitoring during two long-term trials of citalopram. Presented at the 12th Congress of the European College of Neuropsychopharmacology; London, England, 1999.

26. Calegari L, Gorenstein C, Gentil V, Planeta CS, Nunes-de-Souza R L. Effect of Chronic Treatment with Clomipramine on Food Intake, Macronutrient Selection and Body Weight Gain in Rats, Biological & Pharmaceutical Bulletin. 2007;30:1541-1546.

27. Fernstrom MH, Krowinski RL, Kupfer DJ. Chronic imipramine treatment and weight gain, Psychol Res. 1986;17:269–273.

28. Frank E, Kupfer DJ, Bulik CM, Levenson JA. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord. 1990;20:165–172.

29. Balon R, Yeragani V K, Pohl R, et al. Changes in appetite and weight during the pharmacological treatment of patients with panic disorder, Can J Psychiatry. 1993;28:19-22.

30. Mastronardi C, Paz-Filho GJ, Valdez E, Maestre-Mesa J, Licinio J, Wong M-L. Long-term body weight outcomes of antidepressant-environment interactions, Molecular Psychiatry. 2011;16:265–272.

31. Gobshtis N, Ben-Shabat S, Fride E. Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness.European journal of Pharmacology. 2006;554:155–163.

32. Prince JB, Wilens TE, Biederman JA. A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. 2000;10:193–204.

33. Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D, Henigsberg N, Souery D, Placentino A, Keers R, Gray JM, Dernovsek MZ, Strohmaier J, Larsen ER, et al. Changes in body weight during pharmacological treatment of depression. The International Journal of Neuropsychopharmacology. 2011;14:367-375.

34. Paradis CF et al. Nortriptyline and weight change in depressed patients over 60. Journal of clinical psychopharmacology. 1992;12(4):246-250.

35. Meyerowitz W, Jaramillo J. Antidepressant treatment and weight loss, Current Therapeutic Research. 1992;52:169–174.

36. Daubresse JC, Kolanowski J, Krzentowski G, et al. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study, Obes res. 1996;4:391-396.

37. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine vs sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61:863–867.

38. Afkhami-Ardekani M, Sedghi H. Effect of fluoxetine on weight reduction in obese patients. Indian Journal of Clinical Biochemistry. 2005;20:135–138.

39. Rasmussen J, Johnson A, Stewart B, Palmer K. Paroxetine and fluoxetine on food intake in rats and effect of paroxetine on body weight in depressed patients. European Neuropsychopharmacology. 1991;1:443–444.

40. Folgelson DL. Weight gain during fluoxetine treatment. Journal of Clinical Psychopharmacology. 1991;11:220.

41. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156:1170–1176.

42. Orzack MH, Friedman LM. Weight changes on fluoxetine as a function of baseline weight in depressed patients. Psychopharmacol Bull. 1990;26:327–330.

43. Moon CA, Jesinger DK. The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. Brit J Clin Prac. 1991;45:259–262.

44. Abell CA, Farquhar DL, Galloway SM, Steven F, Philip AE, Munro JF. Placebo controlled double-blind trial of fluvoxamine maleate in the obese. Journal of Psychosomatic Research. 1986;30:143–146.

45. Leinonen E, Skarstein J, Behnke K. Efficacy and tolerability of mirtazapine versus citalopram: A double blind, randomized study in patients with major depressive disorder, Nordic antidepressant study group. Int Clin Psychopharm. 1999;14:329–337.

46. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol. 1999;11:273–278.

47. Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM. Duloxetine versus escitalopram and placebo: An 8-month, double-blind trial in patients with major depressive disorder. Current Medical Research and Opinion. 2007;23:1303–1318.

48. Meyerowitz W, Jaramillo J. Sertraline treatment and weight loss. Current Therapeutic Research. 1994;55:1176–1181.

49. Wise TN et al. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Primary care companion to the Journal of clinical psychiatry. 2006;8(5):269-278.

50. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000;61(9):656-663.

51. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, Lechner-Schoner T, Strauss R, Engl J, Deisenhammer EA, Hinterhuber H, Patsch JR, Ebenbichler CF. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry. 2006;67:421-424.

52. Croft H, Houser TL, Jamerson BD, Leadbetter R, Bolden-Watson C, Donahue R, Metz A. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clinical Therapeutics. 2002;24:662-672.

53. Jain AK, Kaplan RA, Gadde KM et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049–1056.

54. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR Enhances Weight Loss: A 48-Week Double-Blind, Placebo- Controlled Trial.Obesity Research. 2002;10:633–641.

55. de Wita L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P. Depression and obesity: A meta-analysis of community-based studies. Psychiatry Research. 2010;178:230–235.

56. Rashmi D, Kathleen F. Managing weight gain as a side effect of antidepressant therapy. Cleveland Clinic Journal of Medicine. 2003;70(7):614.

57. Zimmermann U, Kraus T, Himerich H, et al. Epidemiology, implications and mechanisms underlying drug induced weight gain in psychiatric patients. J Psychiatr Res.2003;37:193-220.

58. Masand PS. Weight gain associated with psychotropic drugs. Review. Expert Opinion on Pharmacotherapy. 2000;1:7–389.

59. Benazzi F. Weight gain in depression remitted with antidepressants: pharmacological or recovery effect? PsychotherPsychosom. 1998;67:271–274.

60. Harvey BH, Bouwer CD. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharm. 2000;23:90–97.

61. Pai N, Deng C, Vella S-L, Castle D, Huange X-F. Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: Temporally based hypothesis. Asian Journal of Psychiatry. 2012; in press.

62. Paykel ES, Mueller PS, De La Vergne PM. Amitriptyline, weight gain and carbohydrate craving: A side effect. Br J Psychiatry. 1973;123:501-507.

63. Sussman N, Ginsberg D, Bikoff J. Effects of nefazodone on body weight: A pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry. 2001;62:256–260.

64. Rigler SK, Webb MJ, Redford L, Brown EF, Zhou J, Wallace D. Weight outcomes among antidepressant users in nursing facilities. Journal of the American Geriatrics Society. 2001;49:49–55.

65. Himmerich H, Schuld A, Haack M, Kaufmann C, Pollmächer T. Early prediction of changes in weight during six weeks of treatment with antidepressants, Journal of psychiatric research. 2004;38:485–489.

66. Su J-A, Tsang H-Y. Comparison of Weight Changes in Patients Treated with Different Antidepressants: Clinical Experiences in Taiwanese Patients. Chang Gung Medical Journal. 2006;29:154–161.

67. Bossini L, Pierantozzi E, Padula L, Di Rienzo M, Fagiolini A, Castrogiovanni P. Relation between weight and plasma leptin levels in female during antidepressant treatment. European Neuropsychopharmacology. 2008;18:S350-S351.

68. Kivimäki M, Hamer M, Batty D, Geddes JR, Tabak AG,Pentti J, Virtanen M, Vahtera J. Antidepressant Medication Use, Weight Gain, and Risk of Type 2 Diabetes: A population-based study. Diabetes Care. 2010;33:2611–2616.

69. Patten S, Williams J, Lavorato D, Khaled S, Bulloch A. Weight gain in relation to major depression and antidepressant medication use. Journal of Affective Disorders.2011;134:288–293.

70. Adams A, Alsuwaidan M, Kennedy SH, Law CWY, Lo AKS, Lourenco MT. The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS drugs. 2010;24:741.

71. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychopharmacol. 2003;64:22-29.

72. Berkowitz RI, Anthony NF. Obesity, psychiatric status, and psychiatric medications. The Psychiatric clinics of North America. 2005;28:39–54.

73. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP, Branchek TA, Gerald C, Vaysse PJ, Forray C. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med. 2002;8:825-30.

74. Cantu TG, Korek JS. Monoamine oxidase inhibitors and weight gain. Drug Intell Clin Pharm. 1988;22:755–759.

75. Chokka P, Tancer M, Yeragani VK. Metabolic syndrome: relevance to antidepressant treatment. Journal of psychiatry & neuroscience. 2006;31:414.

76. Demyttenaere K, Jaspers L. Review: Bupropion and SSRI- induced side effects. J Psychopharmacological. 2008;22:792-804.

77. Drieling T, Biedermann NC, Schärer LO, Strobl N, Langosch JM. Psychotropic drug-induced change of weight: a review. FortschrNeurol Psychiatr. 2007;75:65-80.

78. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61:37–41.

79. Gadde KM, Xiong GL. Bupropion for weight reduction. Expert Review of Neurotherapeutics. 2007;7:17–24.

80. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol. 1988;8:323–330.

81. Kachur SG, Hannan CL, Ward KE. Antidepressant-induced weight gain. Medicine and Health, Rhode Island. 2005;88:59.

82. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546.

83. Mackle M, Kocsis J. Effects on body weight of the SSRI citalopram. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology; Las Croabas, Puerto Rico, 1998.

84. Ness-Abramof R, Apovian CM. Drug-induced weight gain, Drugs Today (Barc). 2005;41:547-555.

85. Rosmond R, Björntorp P. The role of antidepressants in the treatment of abdominal obesity. Medical Hypotheses. 2000;54:990–994.

86. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder. A review. Clinical Therapeutics. 2010;32:S3–S20.

87. Sussman N, Ginsberg D. Rethinking side effects of the selective serotonin reuptake inhibitors: sexual dysfunction and weight gain. Psychiatric Annals. 1998;28:89–97.

88. Sussman N, Ginsberg D. Effects of psychotropic drugs on weight. Psychiatric Annals. 1999;29:580–594.

89. Tek C, Ratliff JC, Chwastiak L. Pharmacological Treatment of Obesity, Psychiatric Annals. 2011;41:489–495.

90. Tohen M, Baker RW, Altshuler LL. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159:1011–1017.

91. Yanovski S, Yanovski J. Obesity. The New England Journal of Medicine. 2002;346:591-602.


Repository Staff Only: item control page